Limits...
Sipa1l1 is an early biomarker of liver fibrosis in CCl4-treated rats.

Marfà S, Morales-Ruiz M, Oró D, Ribera J, Fernández-Varo G, Jiménez W - Biol Open (2016)

Bottom Line: However, these methods may involve clinical complications and/or present diagnostic uncertainty mainly in the early stages of the disease.In cirrhosis, more biological imbalances were detected as well as multi-organ alterations.In addition, hemopexin and signal-induced proliferation-associated 1 like 1 (SIPA1L1) were selected as potential serum markers of liver fibrogenesis among all the analyzed proteins.

View Article: PubMed Central - PubMed

Affiliation: Biochemistry and Molecular Genetics Service, Hospital Clinic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.

No MeSH data available.


Related in: MedlinePlus

Serum concentration of hemopexin and SIPA1L1 in CCl4-treated rats. (A) Serum hemopexin values obtained from control (n=15), mild/moderate (n=15), severe fibrotic (n=15) and cirrhotic rats (n=17). One-way ANOVA with Newman–Keuls post hoc test was used to evaluate dissimilarities between groups. No differences were found between groups. (B) SIPA1L1 serum levels in control rats (n=20), mild/moderate (n=25) and severe fibrotic rats (n=25) and cirrhotic (n=26). Differences between groups were evaluated by the Kruskal–Wallis test with the Dunn post hoc test. *P<0.05, ***P<0.001 in comparison to the control group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4920198&req=5

BIO018887F4: Serum concentration of hemopexin and SIPA1L1 in CCl4-treated rats. (A) Serum hemopexin values obtained from control (n=15), mild/moderate (n=15), severe fibrotic (n=15) and cirrhotic rats (n=17). One-way ANOVA with Newman–Keuls post hoc test was used to evaluate dissimilarities between groups. No differences were found between groups. (B) SIPA1L1 serum levels in control rats (n=20), mild/moderate (n=25) and severe fibrotic rats (n=25) and cirrhotic (n=26). Differences between groups were evaluated by the Kruskal–Wallis test with the Dunn post hoc test. *P<0.05, ***P<0.001 in comparison to the control group.

Mentions: As shown in Fig. 4A, no differences were detected in the circulating levels of hemopexin between control and CCl4-treated rats, including cirrhotic animals. These results, therefore, failed to confirm hemopexin as a non-invasive biomarker of liver fibrosis/cirrhosis in rats. In contrast, CCl4-treated rats with mild fibrosis showed a significant reduction in the serum concentration of SIPA1L1 as compared to controls. These results were coincident to those found in the label free quantitative LC-MS/MS analysis. Furthermore, this diminution was also observed in rats with severe fibrosis and cirrhosis (Fig. 4B).Fig. 4.


Sipa1l1 is an early biomarker of liver fibrosis in CCl4-treated rats.

Marfà S, Morales-Ruiz M, Oró D, Ribera J, Fernández-Varo G, Jiménez W - Biol Open (2016)

Serum concentration of hemopexin and SIPA1L1 in CCl4-treated rats. (A) Serum hemopexin values obtained from control (n=15), mild/moderate (n=15), severe fibrotic (n=15) and cirrhotic rats (n=17). One-way ANOVA with Newman–Keuls post hoc test was used to evaluate dissimilarities between groups. No differences were found between groups. (B) SIPA1L1 serum levels in control rats (n=20), mild/moderate (n=25) and severe fibrotic rats (n=25) and cirrhotic (n=26). Differences between groups were evaluated by the Kruskal–Wallis test with the Dunn post hoc test. *P<0.05, ***P<0.001 in comparison to the control group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4920198&req=5

BIO018887F4: Serum concentration of hemopexin and SIPA1L1 in CCl4-treated rats. (A) Serum hemopexin values obtained from control (n=15), mild/moderate (n=15), severe fibrotic (n=15) and cirrhotic rats (n=17). One-way ANOVA with Newman–Keuls post hoc test was used to evaluate dissimilarities between groups. No differences were found between groups. (B) SIPA1L1 serum levels in control rats (n=20), mild/moderate (n=25) and severe fibrotic rats (n=25) and cirrhotic (n=26). Differences between groups were evaluated by the Kruskal–Wallis test with the Dunn post hoc test. *P<0.05, ***P<0.001 in comparison to the control group.
Mentions: As shown in Fig. 4A, no differences were detected in the circulating levels of hemopexin between control and CCl4-treated rats, including cirrhotic animals. These results, therefore, failed to confirm hemopexin as a non-invasive biomarker of liver fibrosis/cirrhosis in rats. In contrast, CCl4-treated rats with mild fibrosis showed a significant reduction in the serum concentration of SIPA1L1 as compared to controls. These results were coincident to those found in the label free quantitative LC-MS/MS analysis. Furthermore, this diminution was also observed in rats with severe fibrosis and cirrhosis (Fig. 4B).Fig. 4.

Bottom Line: However, these methods may involve clinical complications and/or present diagnostic uncertainty mainly in the early stages of the disease.In cirrhosis, more biological imbalances were detected as well as multi-organ alterations.In addition, hemopexin and signal-induced proliferation-associated 1 like 1 (SIPA1L1) were selected as potential serum markers of liver fibrogenesis among all the analyzed proteins.

View Article: PubMed Central - PubMed

Affiliation: Biochemistry and Molecular Genetics Service, Hospital Clinic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.

No MeSH data available.


Related in: MedlinePlus